Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL1RAP CAR-T
- Development stage
- Unknown
- Lead developer
- City of Hope National Medical Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
IL1RAP CAR-T is an investigational chimeric antigen receptor (CAR) T-cell therapy targeting the interleukin-1 receptor accessory protein (IL1RAP). IL1RAP is highly expressed on acute myeloid leukemia (AML) blasts and leukemic stem cells but is absent on normal hematopoietic stem cells, making it a promising target for selective AML therapy. Developed by researchers at City of Hope, this therapy aims to overcome challenges in AML treatment such as antigen heterogeneity and a suppressive tumor microenvironment. Recent research has explored the use of microRNA-142 (miR-142) to improve the metabolic fitness, persistence, and antileukemic activity of these CAR-T cells by reducing apoptosis and enhancing glycolysis and oxidative phosphorylation.
- Other names
- IL1RAP-targeted CAR-T cellsIL-1RAP-targeted CAR-T cellsIL 1RAP-targeted CAR-T cellsanti-IL1RAP CAR-Tanti-IL-1RAP CAR-Tanti-IL 1RAP CAR-T
02
Targets
IL1RAP (Interleukin 1 receptor accessory protein)
Beyond the preview
Go deeper on IL1RAP CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL1RAP CAR-T.